CytoSorbents™

HELPING REDUCE DEADLY UNCONTROLLED INFLAMMATION IN HOSPITALIZED PATIENTS WORLDWIDE

NASDAQ: CTSO

Investor Presentation

June 2018

Safe Harbor Statement

This presentation contains “forward-looking statements” pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "intend," "target," “will," “is likely,” "would," "may," or, in each case, their negative, or words or expressions of similar meaning. These forward-looking statements are found at various places throughout this presentation and include information concerning possible or assumed future results of our operations; business strategies; future cash flows; financing plans; plans and objectives of management; any other statements regarding future operations, future cash needs, business plans and future financial results, and any other statements that are not historical facts. Unless otherwise indicated, the terms “CytoSorbents,” “Company,” “we,” “us” and “our” refer to CytoSorbents Corporation. Any or all of the forward-looking statements included in this presentation are not guarantees of future performance and may turn out to be inaccurate. These forward-looking statements represent our intentions, plans, expectations, assumptions and beliefs about future events and are subject to risks, uncertainties and other factors. Many of those factors are outside of our control and could cause actual results to differ materially from the results expressed or implied by those forward-looking statements. Although these expectations may change, we are under no obligation to inform you if they do. Actual events or results may differ materially from those contained in the forward-looking statements. The following factors, among others, could cause our actual results to differ materially from those described in a forward-looking statement: our history of losses; potential fluctuations in our quarterly and annual results; competition, inability to achieve regulatory approval for our device, technology systems beyond our control and technology-related defects that could affect the companies’ products or reputation; risks related to adverse business conditions; our dependence on key employees; competition for qualified personnel; the possible unavailability of financing as and if needed; and risks related to protecting our intellectual property rights or potential infringement of the intellectual property rights of third parties. This list is intended to identify only certain of the principal factors that could cause actual results to differ from those discussed in the forward-looking statements. In light of these risks, uncertainties and assumptions, the events described in the forward-looking statements might not occur or might occur to a different extent or at a different time than we have described. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of the applicable presentation. You are referred to a discussion of important risk factors detailed in the Company’s Form 10-K filed with the Securities and Exchange Commission on March 8, 2018 and other reports and documents filed from time to time by us, which are available online at www.sec.gov.

CytoSorbents is a Leader in Critical Care Immunotherapy

Leading the Prevention or Treatment of
Life-Threatening Inflammation
in the ICU and Cardiac Surgery using
CytoSorb® Blood Purification

CytoSorbents At a Glance

- NASDAQ-traded (CTSO): ~$11.25 per share
- CytoSorb®, is E.U. approved, with 40,000+ treatments; distributed in 45 countries
- Trailing 12-month revenue of $17.0M, including product sales of $15.2M. Blended product gross margins of 74%, with $21.1M in cash (3/31/18)
  - 2017 Deloitte Technology Fast 500 and Frost & Sullivan Global Blood Purification award
- 101 employees with international footprint across two wholly-owned subsidiaries
  - CytoSorbents Medical, Inc - New Jersey, USA
    - Headquarters, ISO 13485 manufacturing, QA/QC, R&D
  - CytoSorbents Europe GmbH: International sales office - Berlin, Germany
- Strategic Partnerships with Fresenius Medical Care, Terumo, Biocon, and Dr. Reddy's
- Strong government support with nearly $22M in grants, contracts, other non-dilutive funding
- Russell Microcap Index with coverage by Cowen, B Riley FBR, HCW, Aegis, Maxim, Zacks

✓ **Expecting rapid growth and operating profitability (on quarterly basis) in 2018**

✓ **On path to potential U.S. approval with U.S. REFRESH 2 pivotal trial in cardiac surgery**

Leadership Background

Phillip Chan, MD, PhD – Chief Executive Officer and President

Former Partner at the $80M NJTC Venture Fund, leading life science investments for 5 years. Co-founder of Andrew Technologies, commercializing its HydraSolve™ lipoplasty device in the U.S. MD/PhD from Yale School of Medicine, internal medical residency at the Beth Israel Deaconess Medical Center at Harvard.

Vincent Capponi, MS - Chief Operating Officer

20+ years experience in the medical device, pharmaceutical and imaging fields. Led the first regulatory approval for the heparin flush syringe, used worldwide in hospitals, and managed manufacturing of > 1 million units/week

Kathleen Bloch, MBA, CPA – Chief Financial Officer

20+ years as CFO of private and public companies. Former Laureate Biopharma CFO, a contract biopharmaceutical manufacturer, and CFO of Silverline Windows, a $750M revenue window manufacturing company with 9 manufacturing plants nationally

Eric Mortensen, MD, PhD - Chief Medical Officer

25 years leading clinical trials for key programs at Pfizer, GSK, and Merck. Most recently Vice President & Therapeutic Area Clinical Head for Inflammation and Immunology at Pfizer, leading the company's global late-stage development organization for programs in inflammation including studies for Enbrel and Xeljanz

Christian Steiner, MD – Vice President of Sales and Marketing

15+ years experience in sales and marketing of extracorporeal therapy and critical care sales at Teraklin for MARS, the first liver failure dialysis technology, and at Pulsion Medical (hemodynamic monitoring)

Christopher Cramer, MS, MBA – Vice President of Business Development

15+ years experience in business development and commercial experience. Former Senior Director of New Venture Development at Johnson & Johnson, and previously at PwC Consulting

Uncontrolled Inflammation is Deadly

Sepsis

Trauma

Influenza

Burn Injury

Millions Die Of Uncontrolled Deadly Inflammation Each Year



Lung Injury



Cytokine Release Syndrome

Pancreatitis

Surgical Complications



Liver Failure

CytoSorbents™

Massive Inflammation Causes Organ Failure

Organ failure occurs when vital organs stop working,
causing nearly half of all deaths in the ICU.







Little can be done to prevent or treat organ failure today

CytoSorbents™

No Ideal Options to Treat Severe Inflammation

Anti-Inflammatory (too weak)

NSAIDs

Aspirin

Anti-cytokine antibodies

Anti-integrin antibodies

Anti-oxidants

Immunosuppressive (too strong)

Corticosteroids

Chemotherapy

Organ transplant Anti-rejection drugs

Radiation

Immune system ablation

Anti-leukocyte Abs

CytoSorb Bridges the Gap

CytoSorbents™

Anti-Inflammatory (too weak)

NSAIDs

Aspirin

Anti-cytokine antibodies

Anti-integrin antibodies

Anti-oxidants

Immunosuppressive (too strong)

Corticosteroids

Chemotherapy

Organ transplant
Anti-rejection drugs

Radiation

Immune system ablation

Anti-leukocyte Abs

CytoSorb® Reduces the Fuel to the Fire

- CytoSorb® targets the $20+ billion opportunity in critical care and cardiac surgery
- Approved in the European Union as the first specifically approved extracorporeal cytokine adsorber
- Broad indication for use where cytokines are elevated
- Removes cytokines and many other inflammatory mediators such as free hemoglobin, bacterial toxins, myoglobin, and activated complement
- Safe and well-tolerated: 40,000+ cumulative treatments delivered, up from 23,000 a year ago

*CytoSorb is not yet approved in the U.S.

Patented Blood Purification Technology

The underlying blood purification technology is based on biocompatible, highly porous polymer beads that act like tiny sponges to remove harmful substances from blood



Each bead is about the size of a grain of salt

- Proprietary patented technology with multiple patents pending worldwide
- Manufactured at our ISO 13485 certified facility in New Jersey
- One of the highest grade medical sorbents on medical market today

CytoSorb is “Plug and Play”

Compatible with Existing Dialysis and Heart-Lung Machines



- Place a temporary dialysis catheter in a major vein
- Connect the device to a standard dialysis, ECMO, or heart-lung machine found in hospitals worldwide
- Pump blood out of the body and through the cartridge
- The polymer beads directly contact blood and remove unwanted or toxic substances
- “Purified” blood is pumped back into the patient
- Can treat 70+ total blood volumes per 24 hour treatment
- Each treatment uses a new cartridge

Goal: To Prevent or Treat Organ Failure

Improve Patient Outcome and Survival

Decrease Costs Of ICU and Patient Care

Sepsis



ARDS



Burn Injury

Trauma

Pancreatitis

Influenza

Surgical

The Potential to Revolutionize Critical Care Medicine

Refractory Septic Shock

CytoSorbents™

Prospective, single arm study in 20 patients with refractory late-stage septic shock using CytoSorb aggressively every 12 hours with a new cartridge

- Patients had refractory shock despite high doses of vasopressors, respiratory failure requiring mechanical ventilation, oligo-anuric kidney failure requiring dialysis, and lactate > 8 mmol/L

- Results from the CytoSorb Greifswald Study
  - Resolution of shock in 65% of patients treated with CytoSorb
  - 28-day survival was 45%, a 30-40% absolute improvement over expected (0-10%)
  - Reduction of IL-6 from an initial average of 87,000 pg/mL to below 10,000 pg/mL after 24 hours of treatment

- A similar population (n=16) receiving standard of care but no CytoSorb therapy, where shock could not be reversed, also on mechanical ventilation with an initial lactate level of 6.1 ± 4 mmol/L, and 75% requiring renal replacement therapy had a mortality of 100% at 28 days.*

- Conrad, M., et. al., "Early prediction of norepinephrine dependency and refractory septic shock with a multimodal approach of vascular failure", J Crit Care, 2015; 30:739-743.
- Friesecke, S, et.al.,"Extracorporeal cytokine elimination as rescue therapy in refractory septic shock: a prospective single center study", J Artif Organs 2017 Sep; 20(3):252-259.

Universitätsmedizin GREIFSWALD

Vasoplegia and Heart Transplantation

Prospective, single arm observational study, where propensity score matching of a total of 84 heart transplant patients (60 control, 24 treatment using CytoSorb during surgery) yielded a total of 16 matched pairs of control and treatment patients

- Post-operatively, patients are prone to developing severe vasoplegia and shock, requiring vasopressors
- When CytoSorb was used intra-operatively in a bypass circuit during cardiopulmonary bypass, the need for norepinephrine was significantly lower 24 hours after surgery (0.14 vs 0.30 ug/kg*min control, p=0.04) and 48 hours after surgery (0.06 vs 0.32 ug/kg*min, p=0.05)
- Despite less need for vasopressors, treatment patients maintained comparable hemodynamic parameters
- Fewer cases of acute or acute on chronic renal failure requiring dialysis (2 vs 4 cases control, p=0.03) and a trend to less acute kidney injury, shorter mechanical ventilation, shorter ICU stays in the treatment group
- No deaths in the treatment group, vs 2 deaths in control, in 30 days after surgery

- Nemeth E., et. al., "Impact of intraoperative cytokine adsorption on outcome of patients undergoing orthotopic heart transplantation – an observational study" Clinical Transplantation , accepted manuscript online 29 Jan 2018

Seasonal Influenza

- Seasonal influenza in the US (CDC data)





- Current 2017-18 US epidemic is particularly severe
  - Poor vaccine coverage, virulent H3N2 strain, widespread
- In addition to very young and elderly, otherwise healthy people are dying from influenza
  - Cytokine storm, severe inflammation and rapid organ failure
  - Complications including secondary pneumonia and sepsis
- CytoSorb has recently been used to help treat about 2 dozen cases in Europe and India
  - Primary treatment of severe viral sepsis
  - Treatment of septic shock and multiple organ failure
  - With ECMO or dialysis



Case Report: Influenza

56 year old man with documented swine (H1N1) influenza with multiple organ failure. Interferon levels were undetectable

Treatment day	1	2	3	4	5	6	7
IL-6 (before) pg/mL	8,076	1,025	527	172	117	120	107
IL-6 (after) pg/mL	2,621	663	289	76	110	111	94
IL-6 (% change)	-68%	-35%	-45%	-56%	-6%	-8%	-12%



Expanded Label Targets Liver Failure and Trauma

- Last month, we received European regulatory approval to expand the use of CytoSorb to reduce bilirubin – elevated in liver disease, and myoglobin – elevated in trauma, from blood
- This is expected to expand the market significantly to directly include chronic liver disease and liver failure, as well as severe trauma
- 50 million people suffer from chronic liver disease due to chronic hepatitis, alcoholism, and non-alcoholic fatty liver (NASH), leading to 1 million deaths from chronic liver disease, and another 1 million from hepatic cancer
  - CytoSorb has been used as a liver dialysis therapy in numerous cases showing both bilirubin reduction, and significant clinical benefits including hepatic coma reversal
- 56 million hospitalizations in trauma worldwide each year with approximately 5 million deaths. Severe crush injury of muscle releases myoglobin, called rhabdomyolysis, which can precipitate kidney failure, and increase the risk of death
  - There have been many uses of CytoSorb to treat trauma, expected now to increase

CAR-T Cell Immunotherapy and CRS

- CAR-T cell cancer immunotherapy is a blood cancer treatment breakthrough.
- However, ~40-50% of patients can develop severe, high grade cytokine release syndrome (CRS), a cytokine storm that can lead to rapid organ failure and potentially death
- CytoSorb® was specifically designed to control cytokine storm and CRS and has already successfully treated a dozen cases of the closely related disease hemophagocytic lymphohistiocytosis (HLH)
- With FDA approvals of Kymriah (Novartis) and Yescarta (Gilead), with EU approvals pending, CytoSorb® could be used as second line to tocilizumab, but before steroids
- In March 2017, the pioneer of CAR T-cell immunotherapy, Dr. Carl June at University of Pennsylvania, joined our Scientific Advisory Board

The World Needs CytoSorb®

CytoSorbents™



H1N1













Blood Purification Alternatives

CytoSorbents™

Blood Compatible Sorbents	Blood Incompatible Sorbents	HMCO Filters

CytoSorb
CytoSorbents



CPFA - Bellco
I.M.P.A.C.T - Hemolife

EMiC2 - Fresenius

SepteX - Baxter
Oxiris - Baxter
Theranova - Baxter

CytoSorb

CytoSorbents™

40,000+ Treatments

45 Countries Worldwide with E.U.

Critical Care

Cardiac Surgery

60+ Investigator Initiated Studies

United States

Cardiac Surgery

REFRESH I ✓

↓

REFRESH 2
Started
April 2018

↓

FDA
2020

CytoSorb® Is Like a High Margin Razorblade

- High margin “razorblade” fully compatible with existing installed base of “razor” blood pumps: Dialysis/CRRT, ECMO machines (ICU), heart-lung machines (OR)
- Blended gross margins are 74%, expected to rise with new plant (1H 2018)
- Average Direct Selling Price is approximately $1,000 per cartridge
- Approximately 1 - 10 cartridges are typically used per patient
  - Open heart surgery: 1-2 cartridges
  - Sepsis: 3-5 cartridges or roughly 1 day in the ICU
- In Germany, 400 hospitals have >400 beds. Each hospital typically sees 300-600 sepsis patients per year. At 3-5 cartridges per patient:
  - Revenue per patient = ~$3,000-5,000
  - Potential revenue per hospital = $1-3M for sepsis alone
- In 2016, one German hospital achieved sales >$1M, validating revenue model

Direct Sales: Focused on 5 Countries

CytoSorbents' direct sales force focused on most major university and public hospitals in Germany, Austria, Switzerland, Belgium and Luxembourg. German market alone is $1.0-1.5 billion

Dr. Christian Steiner, MD
Vice President – Sales and Marketing and General Manager CytoSorbents Europe GmbH

Stefan M. Baudis
International Sales Director

Dr. Joerg Scheier, MD
Senior Medical Director Europe

Dr. Volker Humbert, MD
Senior Manager - Clinical Affairs

Franziska Preissing
Senior Manager – Reimbursement & Health Economics

Patrick Waltrich
Senior Manager – Finance/Operations

Kristin von Hammerstein
Marketing Manager

Dominik Gutzler
Head of Product Management

Dr. Rainer Kosanke, PhD
Director Scientific Affairs Europe

Alexandru Bojan
Regional Sales Director

Bettina Sabisch
Regional Sales Director

Christian Tembaak
Regional Sales Director

Winfried Dramburg
Regional Sales Director

Uwe Gerks
Sales Director Central Europe

Hans-Juergen Kraus
Regional Sales Manager Southern Germany

Matthias Hoeldtke
Regional Sales Manager Southeast Germany

Andreas Gassmann
Sales Representative Southern Germany

Christian Koptik
Regional Sales Manager Austria

Daniel Gadke
Regional Sales Manager Northern Germany

Martin Heinzinger
Regional Sales Manager Central Germany

Christin Preiss
Executive Admin

Martin Scherer
Regional Sales Manager Southwest Germany

Andreas Pendleder
Regional Sales Manager Western Germany

Marco Dietrich
Regional Sales Manager Northeast Germany

Oliver Lupoli
Country Sales Manager Switzerland

Brigitta Waldmueller
Sales Manager/Application Specialist Austria

Josephine Kraus
Administrative Support

Dr. Maria Stevenson
IT Management

Patrick Hunneshagen
Congress Management National

Harriet Adamson
Clinical Research Manager

Eva Wechsler
Application Specialist

Anke Applehoff
Application Specialist

Pamela Leckie
Application Specialist International

Paolo Balboni
Application Specialist Internationalt

Petra Hoffman
Sales Assistant/Customer Support

Fernanda Goncalves Zawieja
Sales Assistant/Customer Support

Jaqueline Bloch
Sales Assistant Customer Support

Dedicated Reimbursement In Germany

- CytoSorb achieved a permanent, dedicated reimbursement code in Germany
  - Most important market and the largest medical device market in Europe and third largest in the world
- Was achieved rapidly through the initiative and strong support of several major medical societies across different medical specialties, helping to demonstrate the broad support of our therapy by physicians in the country
- Reimbursement rate was negotiated by individual hospitals in 2017, resulting in significantly higher reimbursement in most many hospitals
- We expect direct sales momentum to accelerate into 2018 as the impact of this higher reimbursement is being felt

CytoSorb® Distributed in 45 Countries

26

Four Major Partnerships, Potential for More



Partnered with leading multinational corporations:
Fresenius Medical Care, Terumo Cardiovascular, Biocon Ltd, and Dr. Reddy's Laboratories

* Companies listed here are used simply as examples of companies in these respective verticals. We make no other representations as to our relationship with any of these companies.

Expanded Fresenius Partnership

- CytoSorbents renewed and expanded its partnership with Fresenius Medical Care in January 2017
- Extension on exclusive distribution of CytoSorb for critical care applications in France, Poland, Denmark, Norway, Sweden, and Finland through 2019
- Guaranteed minimum quarterly orders and payments of CytoSorb evaluable every 1.5 years
- Co-marketing agreement across all of the countries where CytoSorb is sold, where possible
  - Adds to the “effective” sales force in each country
  - Fresenius has provided written endorsement of CytoSorb for the multiFiltrate platform

We have launched our co-marketing effort in 5 countries and plan to ramp up to other countries soon

Launched in December

- Entered into a multi-country strategic partnership with Terumo Cardiovascular Group, a global leader in medical devices for cardiac and vascular surgery
- Initial exclusive distribution of CytoSorb® CPB Procedure Pack for intra-operative use during cardiac surgery in France, Denmark, Norway, Sweden, Finland, and Iceland
- Launched December 2016
- We believe this strategic partnership opens the door to potential expansion to other countries, such as Japan – the second largest medical device market in the world

U.S. Approval Targets Cardiac Surgery

- Heart disease is the leading cause of death worldwide driven by smoking, unhealthy lifestyles, and an aging population
- ~1M cardiac surgeries performed annually in U.S. and E.U.
  - Coronary artery bypass graft surgery
  - Valve repair or replacement
  - Heart or lung transplantation
  - Congenital defect repair
  - Aortic reconstruction



- Complex cardiac surgeries require long heart-lung machine pump times, resulting in:
  - ⬆ Hemolysis and free hemoglobin
  - ⬆ Inflammatory mediators, cytokines, and activated complement

Severe inflammation, nitric oxide scavenging, and reduced blood flow can lead to kidney, lung, and/or heart failure in many patients following surgery

U.S. REFRESH 1 Trial

REduction in FREe Hemoglobin

REFRESH

CytoSorbents™

- 46-patient, eight-center trial evaluating the safety and efficacy of intra-operative use of CytoSorb® in a heart-lung machine during elective, non-emergent complex cardiac surgery with heart-lung machine time ≥ 3 hours

- Working with major cardiac surgery centers
  - Baylor and Texas Heart Institute
  - Baystate Medical Center
  - Columbia University
  - Cooper University Hospital
  - University of Kentucky
  - University of Maryland
  - University of Pennsylvania
  - University of Pittsburgh

CPB Length	Mean Reduction of pfHb (mg/dL)	P-value
3.0	35 mg/dL	0.09
3.5	48 mg/dL	0.05
4.0	61 mg/dL	0.05
4.5	74 mg/dL	0.07

- First RCT using CytoSorb in high risk cardiac surgery
  - Demonstrated safety
  - Identified valve replacement patients who are the highest levels of peak pfHb
  - Demonstrated that CytoSorb significantly reduces pfHb by 35-40% and activated complement during treatment in this population

- Data from the REFRESH 1 Trial was selected for podium presentation at the American Association of Thoracic Surgery (AATS) conference in May 2017 and was submitted for publication

REFRESH 2 - AKI Targets US Approval

Pivotal, multi-center RCT using CytoSorb intraoperatively to reduce the incidence or severity of acute kidney injury (AKI) in high risk cardiac surgery

- The development of even mild AKI after surgery predicts 1 and 5 year mortality and progression to chronic kidney disease
- Trial design approved by FDA:
  - Up to 400 patient, 20-25 center 1:1 randomized, controlled PMA trial in elective, valve replacement or aortic reconstruction with hypothermic cardiac arrest
  - Intervention: Standard of care (control) or Standard of care + CytoSorb intraoperatively
  - Primary endpoint: Postoperative acute kidney injury (AKI)
  - Secondary clinical and cost-effectiveness endpoints: Reduction in other organ injury (incidence of stroke, time on mechanical ventilation, hemodynamic stability), days in the ICU
  - Expected study completion: 2019 with potential 2020-21 FDA approval
  - Cost: Approximately $12M spread out over 3 years
- First patient enrolled, six sites now active, with a total of 26 sites in various stages of evaluation, qualification, and initiation

German Govt Funding REMOVE Endocarditis Trial

- Infective endocarditis (heart valve infection) occurs when bacteria seeds a heart valve from IV drug abuse and dirty needles, or from dental procedures
- The incidence of endocarditis is rising due to the opiate crisis
- Patients often require open heart surgery valve replacement but are very hemodynamically unstable before, during, and after surgery due to a combination of sepsis and heart valve destruction
- Intraoperative CytoSorb has been used to help stabilize such patients peri-operatively with good success
- The German Federal Ministry of Education and Research is funding a 250 patient, multi-center, randomized, controlled study (REMOVE) using CytoSorb during valve replacement open heart surgery in patients with infective endocarditis. 22 patients enrolled at 3 sites, 3 additional sites to start soon
- Primary endpoint is improvement of SOFA score
- Enrolled 29 patients with 6 centers, 3 more sites being added

HemoDefend Nearing U.S. Pivotal Trial

- 100M pRBC units transfused each year worldwide
- Many companies targeting decreased infectious blood risk – NAT testing, pathogen reduction
- HemoDefend pRBC is a point-of-transfusion in-line filter focused on reduction of non-infectious contaminants that can cause transfusion reactions ranging from fever and allergic reactions, to transfusion related acute lung injury (TRALI) – the leading reported cause of transfusion related death that occurs in 1 to 5,000 transfusions
- HemoDefend pRBC reduces antibodies, cytokines, free hemoglobin, bioactive lipids, and many other substances that can cause transfusion reactions
- The development of HemoDefend pRBC has been generously supported by National Heart, Lung, and Blood Institute (NHLBI – a division of NIH), and U.S. Special Operations Command (USSOCOM)
- Have met with the FDA informally, with the support of NHLBI, and expect to initiate a pivotal study within 9-12 months that is designed to lead to U.S. approval

Quarterly Product Sales

Quarter over quarter product sales continue to advance with our 23rd consecutive quarter of year-over-year growth



Trailing Twelve Months Product Sales

Over the past three years, the compound growth rate of return ("CAGR") on product sales was 67%



2018: Rapid Growth & Operating Profitability

Targeting rapid growth and the achievement of operating profitability* on a quarterly basis later this year

- CytoSorb is a high clinical impact “need to have” device that commands strong ASPs and reimbursement
- CytoSorb has a very profitable, high margin disposable business model
- Hybrid sales model leveraging direct sales with low cost distributor and partner sales keeps the company lean and fixed costs low
- We control manufacturing and directly benefit from scaled manufacturing and COGS reductions. New plant that will come online this month will drive gross margin expansion
- New corporate tax rate drop from 35% to 21% enhances profitability and extends life of our significant net operating losses to offset future tax liabilities – generating cash

More than $0.50 on every dollar of sales is expected to drop to EBITDA

*Excluding non-cash expenses and clinical trial costs

Gaining Broader Industry Accolades

- Winner of 2017 Global Frost & Sullivan Product Leadership Award in Blood Purification

"There were many factors that led to our selection of CytoSorb® for this year's Global Product Leadership Award," said Frost & Sullivan Research Analyst Aish Vivek. "Among the most important was the recognition that this innovative product is surprisingly well-positioned to help solve two long-standing, difficult, and tightly linked fundamental problems with hospital medicine today. These include the high rates of death from common critical illnesses such as sepsis that have no approved treatment, and the resulting staggering costs and losses in critical care that are financially crippling hospital networks and healthcare systems throughout the world."

- Recognized on the 2017 Deloitte Technology Fast 500 as one of the fastest growing companies in North America
  - 293% revenue growth from 2013-2016
  - 7th of 21 medical device companies





RANK	COMPANY NAME	% GROWTH
29	STRATA Skin Sciences, Inc.	6,251%
77	Convergent Dental	2,002%
131	Nevro	872%
178	ViewRay, Inc.	604%
259	Invuity Medical Inc.	352%
264	Intersect ENT, Inc.	346%
297	CytoSorbents Corporation	293%
306	AxoGen, Inc.	275%
314	Dexcom, Inc.	265%
352	Semler Scientific, Inc.	227%
369	Wound Management Technologies, Inc.	219%
371	Corindus Vascular Robotics, Inc.	217%
405	Penumbra, Inc.	196%
416	Tandem Diabetes Care, Inc.	190%
421	Iradimed Corporation	187%
437	NanoString Technologies	175%

Upcoming Milestones

- Ongoing progress in international sales
- Operating profitability targeted in 2018
- Potential new partnerships and expansion of existing partnerships
- Ramping of pivotal REFRESH 2 study
- Publications of clinical and research data
- Greater investor awareness through investor meetings, conferences, non-deal roadshows

CytoSorbents Investment Summary

CytoSorbents is strongly positioned and on track to have strong growth in 2018

- Established, well-run U.S. medtech but with a biotech profile, nearing critical mass
- Strategically positioned to address some of the largest, most visible, unmet medical needs worldwide in critical care, cardiac surgery, cancer immunotherapy, and others
- Highly profitable “razorblade” in someone else’s “razor” business model
- Significant CytoSorb® sales growth and expected gross margin expansion and near-term operating profitability
- Excellent validation by customers, partners, and government agencies
- Undiscovered by most investors, but positioned for broader awareness
- Visibility on multiple potential exits for investors

CytoSorbents™

Working to Save Lives Through Blood Purification

NASDAQ: CTSO
Dr. Phillip Chan, MD, PhD – CEO
pchan@cytosorbents.com